Imported HIV drugs are continuously approved for clinical use in China

Source: Ding Xiangyuan 2015-2-4 Burkina Faso, Africa, because of AIDS, 11 year old Elyse lost her father when she was young, and her mother was infected with HIV, Elyse also had many signs and symptoms of AIDS The picture shows Elyse standing in the field exhausted According to the monitoring of insight – China Pharma data database, the HIV compound drug emtricitabine / rilpivine / tenofovir dispersil fumarate jointly developed by Gilead and Johnson was approved for clinical use in China on January 28, 2015 The clinical application was approved on July, and the current status is "under approval" This is the first time Gilead has cooperated with Johnson & Johnson in 2009 to develop a fixed dose compound drug composed of Johnson & Johnson lipirvine and Gilead truvada (enrotabine / tenofovir fumarate) The drug was approved for marketing in the United States (trade name complera) and Europe (trade name eviplera) in August and November 2011, respectively, with q1-q3 sales of $880 million in 2014 Since then, Gilead and Johnson continue to expand the scope of cooperation In 2011, they jointly developed a compound drug composed of Johnson darunovir and Gilead tybost (cobicistat) According to the 2009 supplemental agreement, Gilead will also launch a new study to replace tenofovir axetil with tenofovir As the absolute leader in the field of anti infection, Gilead has made continuous efforts in the Chinese market It has just obtained the clinical application of hepatitis C drug sofosbuvir, and then the clinical application of HIV compound drug has also been approved The single drug of GSK, dolutegravir, was approved in clinical practice Following the approval of Gilead compound combination drug, dolutegravir, a health care company affiliated to GSK, was approved in clinical practice on January 29, 2015 At present, the handling status is "in review and approval" This is the fourth drug that GSK has been approved in China since 2015 Dotiravir is an HIV integrase inhibitor, which can prevent HIV from entering cells and can be used in combination with other antiretroviral drugs The drug was approved for marketing in the United States and Europe in August 2013 and January 2014, respectively, under the trade name tivicay Tivicay has performed well since its launch, and its sales have grown rapidly, which to some extent made up for the loss of GSK due to the decrease of other drugs' revenue At the same time, GSK plans to launch an IPO of its HIV healthcare company in 2015 Latiravir (trade name: aitsheng) from mosadong is the only integrase inhibitor on the market in China Now it seems that the emergence of strong competitors will make latiravir no longer the only choice for HIV patients to integrate enzyme inhibitors